News

Dividend growth stocks can make for excellent long-term investments. Their ongoing rate increases allow investors to generate more in dividend income than if they were to just invest in a stale

A few years ago, in the race to launch a COVID-19 vaccine, Pfizer (NYSE: PFE) stock was a hot buy after the company ended up with a highly successful product in Comirnaty. The uncertainty

When you look at the stock market, valuations can seem stretched for a lot of the megacap names -- not all -- but there are still plenty of deals to be had. In today's video, I will look into a few

Pfizer (NYSE: PFE) investors have been through a lot of ups and downs over the past few years. If you've been on the sidelines, now could be a great time to buy the stock.

Shares of Pfizer have been

Eli Lilly and Novo Nordisk are, so far, the kings of the weight-loss gold rush. Thanks to their medicines, Zepbound and Wegovy, billions in new revenue inflows are assured in the near term.

But

Every good thing must come to an end -- and, eventually, the bull market we're experiencing will, too. Long-term investors must prepare for that to happen at some point.

One of the best ways to do

You're probably familiar with the old adage, "April showers bring May flowers." And you probably know the punchline to the question, "What do May flowers bring?" (The answer: Pilgrims.)

But what

When it comes to dividend investing, some investors like to invest for income, and if you are searching for income, this is the video for you. Today, we will be looking at three dividend stocks that

Medtronic (NYSE: MDT) is a top healthcare company and a leading maker of medical devices. At a market cap of more than $100 billion, the business has soundly established itself in the industry. It

The pandemic-influenced revenue gusher from which pharmaceutical giant Pfizer (NYSE: PFE) benefitted a few years ago has trickled down to a small stream. As a result, share prices have fallen and

Fool.com contributor Parkev Tatevosian reviews Pfizer (NYSE: PFE) stock for passive income investors.

*Stock prices used were the afternoon prices of May 28, 2024. The video was published on May

One week ago, medical device maker Medtronic (NYSE: MDT) surpassed Wall Street's sales and earnings targets. Despite the earnings beat, and despite giving guidance that mostly matched analysts'

Since its spinoff from Pfizer in 2013, animal healthcare behemoth Zoetis (NYSE: ZTS) has seen its cash from operations nearly quintuple as a stand-alone company. Powered by a diverse array of animal

AstraZeneca (NASDAQ: AZN), recognized as the world's sixth-largest pharmaceutical entity by market capitalization, made a bold proclamation in May 2014. The company set an ambitious goal of

Successful investors think about the future by focusing on what the new opportunities might be. They also pay attention to threats that could emerge that might impact the stocks they own. Sometimes

Sometimes, misperceptions can work in investors' favor. When others think the outlook for a stock isn't so great, you can win big if that view is overly pessimistic.

Several stocks that pay

As two of the world's largest and most prolific drugmakers, Pfizer (NYSE: PFE) and AstraZeneca (NASDAQ: AZN) both have grand visions for how to grow even larger over the coming years. And with

If you're looking for an investment in the pharmaceutical sector and you don't already own shares of Amgen (NASDAQ: AMGN), it might be worth considering a purchase. The company's development of

AstraZeneca (NASDAQ: AZN) is embarking on a fresh business plan that will see it grow significantly between now and 2030. If it succeeds, it'll be a company that's even more prominent in the global

Does the stock market feel overbought to you? After watching the benchmark S&P 500 index climb about 28% over the past year, nobody can blame value-conscious investors for thinking twice before

A sum of $500 might not seem like much of an investment, but if you select the right pharmaceutical stocks -- and are patient enough to hold them forever -- history shows you'll have a very high

Vertex Pharmaceuticals (NASDAQ: VRTX) is a fast-growing pharmaceutical company that investors have been bullish on for years. The business generates billions in revenue from cystic fibrosis drugs